Identification and hit-to-lead exploration of a novel series of histamine H4 receptor inverse agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 8, 2010, Pages 2516-2519

  Cramp, Sue ^a   Dyke, Hazel J ^a   Higgs, Christopher ^a   Clark, David E ^a   Gill, Matthew ^a   Savy, Pascal ^a   Jennings, Neil ^a   Price, Steve ^a   Lockey, Peter M ^a   Norman, Dennis ^a   Porres, Soraya ^a   Wilson, Francis ^b   Jones, Alison ^b   Ramsden, Nigel ^b   Mangano, Raffaella ^b   Leggate, Dan ^b   Andersson, Marie ^b   Hale, Richard ^b  

^a Argenta Discovery Ltd   (United Kingdom)

^b Cellzome Ltd   (United Kingdom)

Author keywords

Hiatamine H4; Hit to lead

Indexed keywords

HISTAMINE AGONIST; HISTAMINE H4 RECEPTOR; HISTAMINE H4 RECEPTOR ANTAGONIST; HISTAMINE H4 RECEPTOR INVERSE AGONIST; LIGAND; N METHYLAMINOPYRROLIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG IDENTIFICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STABILITY; ENANTIOMER; IC 50; MICROSOME; NONHUMAN; RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DISCOVERY; HISTAMINE ANTAGONISTS; INHIBITORY CONCENTRATION 50; MACACA FASCICULARIS; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE; STEREOISOMERISM;

EID: 77950024641     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.02.097     Document Type: Article

References (13)

1. Leurs R., Chazot P.L., Shenton F.C., Lim H.D., and de Esch I.J.P. Br. J. Pharmacol. 157 (2009) 14
2. Huang J.-F., and Thurmond R.L. Curr. Allergy Asthma Rep. 8 (2008) 21
3. Smits R.A., Leurs R., and de Esch I.J.P. Drug Discovery Today 14 (2009) 745
4. Thurmond R.L., Gelfand E.W., and Dunford P.J. Nat. Rev. Drug Disc. 7 (2008) 41
5. Kiss R., and Keseru G.M. Expert Opin. Ther. Patents 19 (2009) 119
6. Zampeli E., and Tiligada E. Br. J. Pharmacol. 157 (2009) 24
7. Clark D.E., Higgs C., Wren S.P., Dyke H.J., Wong M., Norman D., Lockey P.M., and Roach A.G. J. Med. Chem. 47 (2004) 3962
8. Arienzo R., Clark D.E., Cramp S., Daly S., Dyke H.J., Lockey P., Norman D., Roach A.G., Stuttle K., Tomlinson M., Wong M., and Wren S.P. Bioorg. Med. Chem. Lett. 14 (2004) 4099
9. Arienzo R., Cramp S., Dyke H.J., Lockey P.M., Norman D., Roach A.G., Smith P., Wong M., and Wren S.P. Bioorg. Med. Chem. Lett. 17 (2007) 1403
10. Jablonowski J.A., Grice C.A., Chai W., Dvorak C.A., Venable J.D., Kwok A.K., Ly K.S., Wei J., Baker S.M., Desai P.J., Jiang W., Wilson S.J., Thurmond R.L., Karlsson L., Edwards J.P., Lovenberg T.W., and Carruthers N.I. J. Med. Chem. 46 (2003) 3957
11. 3H]-histamine dihydrochloride (GE Healthcare), 25 μg human H4 receptor expressing membranes (Euroscreen) and 0.75 mg SPA beads (GE Healthcare) in a total volume of 200 μl. Non-specific binding was determined in the presence of 4 μM histamine dihydrochloride (Sigma-Aldrich). Plates were counted using a Microbeta scintillation counter (Perkin-Elmer).
12. Cowart M.D., Altenbach R.J., Liu H., Hsieh G.C., Drizin I., Milicic I., Miller T.R., Witte D.G., Wishart N., Fix-Stenzel S.R., McPherson M.J., Adair R.M., Wetter J.M., Bettencourt B.M., Marsh K.C., Sullivan J.P., Honore P., Esbenshade T.A., and Brioni J.D. J. Med. Chem. 51 (2008) 6547
13. 35S]-GTPγS (GE Healthcare) and 0.75 mg SPA beads (GE Healthcare) for an additional 30 min. Non-specific binding was determined in the presence of 10 μM GTPγS (Sigma-Aldrich). SPA beads were sedimented by centrifugation and counted using a Microbeta scintillation counter (Perkin-Elmer).